BrosMed Enters the USA Coronary Angioplasty Catheter Market
Release time:
2015-08-01
BrosMed Enters the USA Coronary Angioplasty Catheter Market August 1st, 2015—BrosMed announced that BrosMed Medical and US Endovascular entered into an exclusive agreement to distribute coronary angioplasty catheters in the USA market.
BrosMed Enters the USA Coronary Angioplasty Catheter Market
August 1st, 2015—BrosMed announced that BrosMed Medical and US Endovascular entered into an exclusive agreement to distribute coronary angioplasty catheters in the USA market.
Following the 510(k) clearance of both Artimes and Apollo balloon dilatation catheters, BrosMed entered into a long-term exclusive distribution agreement with US Endovascular for its PTCA pipeline for the United States of America market.
“BrosMed management has a long history in the international marketplace and is proud of its quality and production system as we are ready for a US market launch. We expect that this long-term agreement with USE will benefit both of our strategies,” said Benny Lee, CEO of BrosMed Medical Co., Ltd.
Artimes and Apollo PTCA Technology Highlights:
Apollo is a truly non-compliant, high-pressure post-dilatation catheter, which offers numerous features: folded balloon for crossability, flexibility and exceptional balloon rewrap; spiral extrusion catheter; low crossing profile; enhanced robustness; and non-compliant balloon performance. It has extraordinarily minor 3.0% axial growth and is compatible with a 5F guiding catheter. Balloon sizes are 2.0–5.0mm in diameter and 8–18mm in length. Average burst pressure (ABP) is 30atm.
Artimes is a semi-compliant pre-dilatation catheter offering numerous features: folded balloon for crossability, flexibility and exceptional balloon rewrap; spiral extrusion catheter; and low crossing profile to facilitate physicians and procedures. Balloon sizes are designed for tight lesions and the treatment of CTOs.
“We are extremely excited about the agreement we have with US Endovascular. BrosMed Medical was looking for a distribution partner in the United States with the same philosophy about how to adapt to the changes in this market.”
“Like USE, BrosMed Medical is a very fast-growing entrepreneurial company with offices in China, the Netherlands and India, supporting distributors and physicians globally.”
“This is a significant step forward for BrosMed to increase global sales and to seek US FDA approval for additional coronary and peripheral endovascular devices that will include advanced technology,” said Jos De Korte, VP Sales and Marketing and GM of BrosMed Medical B.V., the Netherlands.
About BrosMed Medical
BrosMed Medical is more than just a company; we are leading the medical device design and manufacturing revolution.
BrosMed Medical develops, manufactures and markets medical devices primarily used by interventional cardiologists, radiologists and vascular surgeons in angioplasty procedures and other minimal invasive devices.
We provide solutions to our customers through innovative design, effective supply chain management, world-class manufacturing, and flexible channels of distribution and through the development or acquisition of innovative technologies.
About US Endovascular (USE)
US Endovascular (USE) is engaged in the procurement, licensing and distribution of medical device products used in peripheral endovascular and coronary procedures. The fundamental premise is to obtain next-generation, clinically relevant products from manufacturers and market them directly to the end user/economic buyer. This approach eliminates all unnecessary layers, significantly reducing cost.
USE’s product portfolio includes next-generation peripheral arterial laser technology (pending FDA 510(k) approval), next-generation PTA and PTCA balloon technology, and peripheral guidewires. These product segments are used in more than 95% of peripheral endovascular and coronary procedures.
In 2015, the estimated size of the US market is 3.4M coronary procedures: 2.1M diagnostic and 1.2M interventional. On average, 2.1 angioplasty balloons (PTCA) are used per procedure, for a total market opportunity of 2.5M units. Until today, the US PTCA market has consisted of only three medical device companies: Medtronic, Abbott Vascular and Boston Scientific. US Endovascular now makes it four, entering the PTCA market with the goal of fundamentally changing the narrative.
Join Us!
Please fill out this form and we will get in touch within 24 hours.
* Note: Please be sure to fill in the information accurately and keep the communication unblocked. We will get in touch with you as soon as possible.
More news
BrosMed Announces Canadian Approval of RevoEdge™ High-Pressure Cutting Balloon
BrosMed Medical today announced Canadian regulatory approval of the RevoEdge™ High-Pressure Cutting Balloon Dilatation Catheter, expanding the company’s presence in North America and marking another milestone in the global commercialization of its specialty coronary portfolio.
2026-09-14
BrosMed Announced CE MDR Approval of VascuGlide™ Microcatheter System
June 15, 2026-BrosMed is pleased to announce that the VascuGlide™ Microcatheter System has received CE MDR certification, marking another significant milestone in the company's commitment to advancing peripheral intervention solutions.
2026-06-18
